Predictors for post-sepsis myocardial infarction (MI) and stroke are yet to be identified due to the competing risk of death.
Methods:
This study included all hospitalized patients with sepsis from National Health Insurance Research Database of Taiwan between 2000 and 2011. The primary outcome was the first occurrence of MI and stroke requiring hospitalization within 180 days following hospital discharge from the index sepsis episode. The association between predictors and post-sepsis MI and stroke were analyzed using cumulative incidence competing risk model that controlled for the competing risk of death.
Results:
Among 42 316 patients with sepsis, 1012 (2.4%) patients developed MI and stroke within 180 days of hospital discharge. The leading 5 predictors for post-sepsis MI and stroke are prior cerebrovascular diseases (hazard ratio [HR]: 2.02, 95% confidence interval [CI]: 1.74-2.32), intra-abdominal infection (HR: 1.94, 95% CI: 1.71-2.20), previous MI (HR: 1.81, 95% CI: 1.53-2.15), lower respiratory tract infection (HR: 1.62, 95% CI: 1.43-1.85), and septic encephalopathy (HR: 1.61, 95% CI: 1.26-2.06).
Conclusions:
Baseline comorbidities and sources of infection were associated with an increased risk of post-sepsis MI and stroke. The identified risk factors may help physicians select a group of patients with sepsis who may benefit from preventive measures, antiplatelet treatment, and other preventive measures for post-sepsis MI and stroke.
StevensonEKRubensteinARRadinGTWienerRSWalkeyAJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med. 2014;42(3):625–631.
2.
KadriSSRheeCStrichJR, et al.Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers Using Clinical Data. Chest. 2017;151(2):278–285.
3.
KaukonenKMBaileyMSuzukiSPilcherDBellomoR. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. Jama. 2014;311(13):1308–1316.
4.
Corrales-MedinaVFAlvarezKNWeissfeldLA, et al.Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. Jama. 2015;313(3):264–274.
5.
Corrales-MedinaVFFatemiOSerpaJ, et al.The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scand J Infect Dis. 2009;41(6-7):511–514.
6.
Corrales-MedinaVFSerpaJRuedaAM, et al.Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine. 2009;88(3):154–159.
7.
Corrales-MedinaVFSuhKNRoseG, et al.Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. Plos Med. 2011;8(6):e1001048.
8.
ElkindMSCartyCLO’MearaES, et al.Hospitalization for infection and risk of acute ischemic stroke: the cardiovascular health study. Stroke. 2011;42(7):1851–1856.
9.
OuSMChuHChaoPW, et al.Long-term mortality and major adverse cardiovascular events in sepsis survivors: a nationwide population-based Study. Am J Respir Crit Care Med. 2016;194(2):209–217.
10.
SmeethLThomasSLHallAJHubbardRFarringtonPVallanceP. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–2618.
11.
VallancePCollierJBhagatK. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?Lancet. 1997;349(9062):1391–1392.
12.
Zanotti-CavazzoniSLHollenbergSM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009;15(5):392–397.
13.
KilickapMGoksulukHCandemirB, et al.Evaluation of acute infection-induced endothelial dysfunction and its potential mediators. Acta Cardiologica. 2011;66(5):581–587.
14.
LeviM. Platelets in sepsis. Hematology. 2005;10(suppl 1):129–131.
15.
DewitteALepreuxSVilleneuveJ, et al.Blood platelets and sepsis pathophysiology: a new therapeutic prospect in critical ill patients?Ann Intensive Care. 2017;7(1):115.
16.
JafarzadehSRThomasBSWarrenDKGillJFraserVJ. Longitudinal study of the effects of bacteremia and sepsis on 5-year risk of cardiovascular events. Clin Infect Dis. 2016;63(4):495–500.
17.
WangHEMooreJXDonnellyJPLevitanEBSaffordMM. Risk of Acute Coronary Heart Disease After Sepsis Hospitalization in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Cohort. Clin Infect Dis. 2017;65(1):29–36.
18.
Dalager-PedersenMSogaardMSchonheyderHCNielsenHThomsenRW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014;129(13):1387–1396.
19.
AustinPCLeeDSFineJP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–609.
20.
VaradhanRWeissCOSegalJBWuAWScharfsteinDBoydC. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care. 2010;48(suppl 6):S96–S105.
21.
WolbersMKollerMTWittemanJCSteyerbergEW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009;20(4):555–561.
22.
BeyersmannJDettenkoferMBertzHSchumacherM. A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Stat Med. 2007;26(30):5360–5369.
23.
AngusDCLinde-ZwirbleWTLidickerJClermontGCarcilloJPinskyMR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310.
24.
ChengCLLeeCHChenPSLiYHLinSJYangYH. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24(6):500–507.
25.
ChengCLKaoYHLinSJLeeCHLaiML. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidem Dr S. 2011;20(3):236–242.
26.
KohlMPlischkeMLeffondréKHeinzeG. PSHREG: a SAS macro for proportional and nonproportional subdistribution hazards regression. Comput Meth Prog Bio. 2015;118(2):218–233.
27.
SerodyJSBerreyMMAlbrittonK, et al.Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transpl. 2000;26(5):533–538.
28.
GlerantJCHellmuthDSchmitJLDucroixJPJounieauxV. Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission. Resp Med. 1999;93(3):208–212.
29.
MerxMWWeberC. Sepsis and the heart. Circulation. 2007;116(7):793–802.
30.
OkamotoKTamuraTSawatsubashiY. Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016;4:23.
31.
ThomasMRStoreyRF. The role of platelets in inflammation. Thromb Haemost. 2015;114(3):449–458.
32.
KapurRZuffereyABoilardESempleJW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194(12):5579–5587.
33.
ManneBKXiangSCRondinaMT. Platelet secretion in inflammatory and infectious diseases. Platelets. 2017;28(2):155–164.
34.
WarkentinTEAirdWCRandJH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003;1:497–519.
35.
RusswurmSVickersJMeier-HellmannA, et al.Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock. 2002;17(4):263–268.
36.
KatzJNKolappaKPBeckerRC. Beyond thrombosis: the versatile platelet in critical illness. Chest. 2011;139(3):658–668.
37.
SempleJWItalianoJEJrFreedmanJ. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264–274.
38.
SempleJWFreedmanJ. Platelets and innate immunity. Cell Mol Life Sci. 2010;67(4):499–511.
39.
TsaiMJOuSMShihCJ, et al.Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015;41(5):806–813.
40.
AkinosoglouKAlexopoulosD. Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res. 2014;133(2):131–138.
41.
GrossAKDunnSPFeolaDJ, et al.Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis. 2013;35(2):147–154.
42.
WinningJNeumannJKohlM, et al.Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010;38(1):32–37.
43.
EisenDPReidDMcBrydeES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012;40(6):1761–1767.
44.
SossdorfMOttoGPBoettelJWinningJLoscheW. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Critical care. 2013;17(1):402.
45.
TonerPMcAuleyDFShyamsundarM. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Critical care. 2015;19:374.
46.
MartinECevikCNugentK. The role of hypervirulent Staphylococcus aureus infections in the development of deep vein thrombosis. Thromb Res. 2012;130(3):302–308.
47.
MejerNGotlandNUhreML, et al.Increased risk of arterial thromboembolic events after Staphylococcus aureus bacteremia: a matched cohort study. J infection. 2015;71(2):167–178.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
